Relapsed/Refractory HER2+ Metastatic Breast Cancer

February 15, 2021
Adam M. Brufsky, MD, PhD

,
Neil M. Iyengar, MD

,
Sara A. Hurvitz, MD

,
VK Gadi, MD, PhD

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.